---
title: "Haisco and Nuvectis sign licensing deal for two drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290680013.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-06-24T08:10:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290680013.md)
  - [en](https://longbridge.com/en/news/290680013.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290680013.md)
---

# Haisco and Nuvectis sign licensing deal for two drugs

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)
- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)

## Related News & Research

- [China's Haisco Gets China’s Nod for Rare Blood Disorder Drug](https://longbridge.com/en/news/293607538.md)
- [Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patients](https://longbridge.com/en/news/293607988.md)
- [Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)](https://longbridge.com/en/news/293777709.md)
- [02:08 ETHaisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH](https://longbridge.com/en/news/293566351.md)
- [Nu Holdings (NU) Following Q1 Results Is The Growth Story Still Undervalued](https://longbridge.com/en/news/293893031.md)